{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000063","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.678354+00:00","generated_at":"2026-05-17T22:12:34.074762+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Xencor appoints Raymond Deshaies, Ph.D. to board of directors","bullets":["Dr. Deshaies is a former SVP of global research at Amgen with 25+ years in biotech.","Received initial option grant with $550,000 Black-Scholes value; vests over 3 years.","Also receives $50,000 annual cash retainer; standard indemnification agreement.","Deshaies co-founded Proteolix (discovered carfilzomib/KYPROLIS) and Cleave Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000063","json":"https://secwatch.observer/filing/0001326732-25-000063.json","markdown":"https://secwatch.observer/filing/0001326732-25-000063.md","text":"https://secwatch.observer/filing/0001326732-25-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000063/0001326732-25-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000063/xncr-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:12:34.074762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}